• Bone mineral density (BMD) is used as an indicator of osteoporosis. BMD is measured and quantified by T-score, whose units are standard deviations relative to that of young, healthy adults (Young Adult Mean [YAM] ). The International Osteoporosis Foundation (IOF) defines osteoporosis as a T-score of -2.5 or lower, i.e., worse. Severe osteoporosis is defined as a T-score of -2.5 or lower, and presence of at least one fragility fracture. 1
• As bone deterioration progresses, i.e., reductions in BMD, the risk of fracture is greatly increased. Other important fracture risk factors are age and fracture history, along with family history, lifestyle, etc. Vertebral and non-vertebral fractures are associated with increased risks of further fractures. Hip and vertebral fractures are also associated with increased mortality. 1
• Drug treatment interventions such as Forsteo ® (teriparatide [rDNA origin] injection) have been shown to reduce the risk of fractures. 2, 3 Teriparatide is approved for up to 24 months of use. 4 • Clinical management of osteoporosis often involves different pharmacologic therapies in a sequential manner. After completion of the teriparatide regimen, antiresorptive (AR) bisphosphonate therapies such are commonly considered.
• Real-world outcomes based on sequential teriparatide-bisphosphonate treatment of severe PMO in Korea are lacking.
BACKGROUND Analysis Model Structure
• Monte Carlo microsimulation model based on a published computer-based simulation cost-effectiveness model 5 ( Figure 1) • 6-month fixed time advance
• Natural mortality and fracture-related excess mortality modeled
• Lifetime time horizon (maximum age 100 years)
• Fractures included in the analysis are hip, clinical vertebral, wrist, and other fractures (proximal humerus, finger, toe, etc.)
• Patients may experience multiple fractures in a given 6-month period
• QALYs and LYs discounted at 5% per year
Base Case Demographics
• Severe PMO patients in Korea,
• BMD T-score -2.5,
• Ages 65-90 years as distributed in Korean population, and
• Two (2) previous osteoporotic fractures (clinical vertebral fractures).
• One of the two previous clinical vertebral fractures is designated to be a historical fracture, which occurred more than 6 months before the beginning of simulation
• The other clinical vertebral fracture is designated to be an incident fracture, which occurred in the six month period immediately before the beginning of simulation
• The two fractures, in combination with the T-score of -2.5, are used to represent severe PMO. The occurrence of the second fracture, i.e., the incident fracture, can be a prompt for the potential use of teriparatide.
Treatments (Tx)
• 2 years of teriparatide followed by 3 years of alendronate (TPTD2+ALN3) vs. 5 years of alendronate (ALN5)
• Efficacy for fracture relative risk reduction (RRR) sourced from literature
• 100% therapy persistence assumed
• Teriparatide is modeled as having fracture RRR while on treatment (24 months), post-treatment (sustained) fracture RRR, and subsequent fracture RRR phaseout (18 months) ( Table 1 ). Figure 2 presents the teriparatide fracture relative risk (RR) values, where RR = 1.0 -RRR.
• Alendronate is modeled as having fracture RRR while on treatment and subsequent fracture RRR phaseout over a period corresponding to the duration of treatment (Table 1) • For sequential teriparatide-bisphosphonate treatment, during the post-teriparatide sustained fracture RRR and subsequent fracture RRR phaseout periods the patients are on alendronate treatment. During these periods, the HIGHER of the two treatments' effective fracture-specific RRRs are utilized.
Fracture Disutility
• Patients who experience a fracture in a given 6-month period have a fracturespecific acute utility multiplier applied to their baseline age-gender utility values for that 6-month period (Table 1) • Subsequent to the 6-month period in which the fracture occurred, patients have a fracture-specific continuing utility multiplier applied to their baseline age-gender utility values (Table 1) Sensitivity Analyses
• Sensitivity analyses performed for 2 years of teriparatide followed by 5 years of alendronate (TPTD2+ALN5) vs. 7 years of alendronate (ALN7)
• Sensitivity analyses performed for BMD T-score -3.0 with 2 previous osteoporotic fractures for TPTD2+ALN3 vs. ALN5 and TPTD2+ALN5 vs. ALN7. 
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DISCUSSION AND CONCLUSIONS
• Teriparatide followed by alendronate may lead to improved fracture and HRQoL outcomes when compared to alendronate only in severe PMO women in Korea.
• Benefits of teriparatide in sequential therapy increase with the severity of PMO as measured by BMD.
• Benefits of sequential therapy after a full regimen of teriparatide depend on durations of subsequent alendronate therapy.
LIMITATIONS
• Real-world fracture RRRs for sequential teriparatide-bisphosphonate treatment were not available. Efficacy assumptions were made based on the utilization of optimal longitudinal fracture-specific RRRs.
• 100% persistence was modeled for the treatment interventions. This is a conservative estimate for teriparatide, as long-term persistence to alendronate does not represent a real-world scenario.
• All computer simulation models are simplifications and cannot exactly replicate or predict real world outcomes.
• A cost-effectiveness analysis (CEA) model was developed to support a study of therapeutic interventions in the treatment of osteoporosis in Korea. The purpose was to estimate fracture (Fx) and health-related quality of life (HRQoL) outcomes (life years [LYs] and quality-adjusted life years [QALYs]) for severe PMO patients using teriparatide followed by AR bisphosphonate alendronate versus only alendronate.
OBJECTIVE
RESULTS
Base Case
• In the base case (T-score -2.5, 2 Fxs) the TPTD2+ALN3 patients had fewer fractures (-173; 4329 vs. 4502) compared to ALN5 patients. Table 2 and Figure 3 present the number of hip, clinical vertebral, wrist, and other fractures per 1000 patients. Table 3 shows that the TPTD2+ALN3 patients had more LYs (+32; 8409 vs. 8377), and more QALYs (+74; 5252 vs. 5178).
Sensitivity Analyses
The results for sensitivity analyses on BMD T-score and duration of treatment are presented in Tables 4 through 9 .
• Tables 4 and 5 show TPTD2+ALN3 vs. ALN5 results for patients with T-score -3.0 and two previous osteoporotic fractures. Tables 6 and 7 show results for TPTD2+ALN5 vs. ALN7 for patients with T-score -2.5 and two previous osteoporotic fractures.
• In the TPTD2+ALN3 vs. ALN5, T-score -2.5, 2 Fxs analysis, the fracture count reduction of 173 osteoporotic fractures is composed mostly of a 136 count reduction in the number of clinical vertebral fractures.
• This is because in the 24 months of teriparatide use, its clinical vertebral fracture 65% RRR is much higher than alendronate's 45%.
• Additionally, in the 18-month teriparatide post-treatment (sustained) clinical vertebral fracture RRR period, teriparatide's clinical vertebral fracture 57% RRR is higher than alendronate's 45%, thus extending use of the effective teriparatide clinical vertebral fracture RRR to 42 months (24+18) for TPTD2+ALN3.
• The teriparatide post-treatment (sustained) non-vertebral fracture RRR (27%) is lower than alendronate's hip fracture RRR (39%), so the effective teriparatide hip fracture RRR is only used for the 24 months of teriparatide treatment. Thus the impact on low-incidence hip fracture counts is minimal for TPTD2+ALN3 vs. ALN5.
• The teriparatide post-treatment (sustained) non-vertebral fracture RRR (27%) is higher than alendronate's non-vertebral fracture RRR (16%), thus extending use of the effective teriparatide non-vertebral fracture RRR to 54 months (24+30) for TPTD2+ALN3. The impact on wrist and other fracture counts is proportionally high, but these are low-incidence fractures.
• All fractures have an associated acute and continuing disutilities, so the reductions in clinical vertebral, wrist, and other fractures result in an increase in QALYS for TPTD2+ALN3 vs. ALN5.
• Clinical vertebral fractures are modeled as having increased mortality risks, so there are resultant increases in both LYs, and thus QALYs, for TPTD2+ALN3 vs. ALN5 due to the reduction in clinical vertebral fractures.
• The lifetime time horizon of the model analysis tends to obscure the positive impact of 24-month teriparatide use. Teriparatide's superior fracture RRR compared to alendronate manifests itself in fewer fractures in this 24-month period, and in the case of clinical vertebral fractures and non-hip fractures over additional 18 and 30-month periods, respectively.
• HRQoL outcomes (QALYs and LYs) are discounted at a relatively high annual rate of 5% per accepted norms in Korea. The impact of excess mortality and long-term continuing fracture-related disutilities avoided with teriparatide use in the first years of the simulation are minimized over the long time horizon.
• Tables 8 and 9 show results for TPTD2+ALN5 vs. ALN7 for patients with T-score -3.0 and two previous osteoporotic fractures.
• Specification of a lower BMD (T-score -3.0 vs, -2.5) and longer duration of postteriparatide alendronate therapy (5 years vs. 3 years) compared to the base case
• TPTD2+ALN5 vs. ALN7 T-score -3.0 was more impactful than TPTD2+ALN3 vs. ALN5 T-score -2.5, preventing 223 fractures (compared to 173), with QALY increases of 104 (compared to 74) and LY increases of 48 (compared to 32).
• The specification of a longer duration of post-teriparatide alendronate therapy (5 years vs. 3 years) for T-score -2.5 results in fewer fractures in both arms of the TPTD2+ALN5 vs. ALN7 analysis compared to the TPTD2+ALN3 vs. ALN5 analysis. This results in more QALYs and LYs in both arms as well.
• TPTD2+ALN5 vs. ALN7 was more impactful than TPTD2+ALN3 vs. ALN5 in the T-score -2.5 analyses, preventing 185 fractures (compared to 173), with QALY increases of 83 (compared to 74) and LY increases of 38 (compared to 32).
• The specification of a lower BMD (T-score -3.0) results in more fractures in both arms of the TPTD2+ALN3 vs. ALN5 analysis compared to the equivalent T-score -2.5 analysis. This results in fewer QALYs and LYs in both arms as well.
• TPTD2+ALN3 compared to ALN5 was more impactful in the T-score -3.0 analysis than in the equivalent T-score -2.5 analysis, preventing 199 fractures (compared to 173), with QALY increases of 92 (compared to 74) and LY increases of 43 (compared to 32). 
